Is Rituximab a Potential New Therapy in Systemic Sclerosis?: New Evidence Indicates the Presence of CD20-Positive B-lymphocytes in Scleroderma Skin.

Frank Wollheim

Is Rituximab a Potential New Therapy in Systemic Sclerosis?: New Evidence Indicates the Presence of CD20-Positive B-lymphocytes in Scleroderma Skin.

Reumatologi och molekylär skelettbiologi

Forskningsoutput: Tidskriftsbidrag › Letter › Peer review

Originalspråk	engelska
Sidor (från-till)	155-155
Tidskrift	Journal of Clinical Rheumatology
Volym	10
Nummer	3
Status	Published - 2004

Ämnesklassifikation (UKÄ)

Klinisk medicin

Tillgång till dokument

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17043493&dopt=Abstract

Citera det här

@article{83d4cefca4bf438a92badbad567e453a,

title = "Is Rituximab a Potential New Therapy in Systemic Sclerosis?: New Evidence Indicates the Presence of CD20-Positive B-lymphocytes in Scleroderma Skin.",

author = "Frank Wollheim",

year = "2004",

language = "English",

volume = "10",

pages = "155--155",

journal = "Journal of Clinical Rheumatology",

issn = "1536-7355",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}